Signaturefd LLC Has $2.19 Million Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Signaturefd LLC grew its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 442.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 138,950 shares of the company’s stock after buying an additional 113,319 shares during the quarter. Signaturefd LLC’s holdings in Dr. Reddy’s Laboratories were worth $2,194,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. grew its position in Dr. Reddy’s Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after acquiring an additional 9,373,412 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Dr. Reddy’s Laboratories by 402.5% in the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company’s stock worth $38,981,000 after purchasing an additional 1,977,419 shares in the last quarter. State Street Corp grew its holdings in shares of Dr. Reddy’s Laboratories by 1.9% during the third quarter. State Street Corp now owns 909,905 shares of the company’s stock worth $72,292,000 after purchasing an additional 16,641 shares during the last quarter. Mondrian Investment Partners LTD increased its stake in shares of Dr. Reddy’s Laboratories by 356.7% in the fourth quarter. Mondrian Investment Partners LTD now owns 648,813 shares of the company’s stock valued at $10,245,000 after buying an additional 506,752 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Dr. Reddy’s Laboratories by 400.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock valued at $8,373,000 after buying an additional 427,573 shares during the last quarter. Institutional investors and hedge funds own 3.85% of the company’s stock.

Analysts Set New Price Targets

RDY has been the topic of a number of research analyst reports. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th.

Dr. Reddy’s Laboratories Stock Up 4.3 %

NYSE RDY opened at $13.23 on Tuesday. The stock has a market capitalization of $11.04 billion, a P/E ratio of 21.06 and a beta of 0.48. Dr. Reddy’s Laboratories Limited has a 52 week low of $12.50 and a 52 week high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The stock has a fifty day moving average of $13.83 and a 200-day moving average of $14.77.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, equities research analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.